Status:
COMPLETED
First-in-Human Single Ascending and Multiple Dose of GLPG0259
Lead Sponsor:
Galapagos NV
Conditions:
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral dose of GLPG0259 compared to placebo. Also, pharmacokinetics (PK) and pharmacodyna...
Eligibility Criteria
Inclusion
- healthy male, age 18-50 years
- BMI between 18-30 kg/m², inclusive.
Exclusion
- significantly abnormal platelet function or coagulopathy
- smoking
- drug or alcohol abuse
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00905138
Start Date
March 1 2009
End Date
June 1 2009
Last Update
February 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS Stuivenberg
Antwerp, Belgium